NASDAQ:EGRX - Eagle Pharmaceuticals Stock Price, News, & Analysis

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

Eagle Pharmaceuticals declared that its Board of Directors has approved a stock buyback plan on Thursday, August 10th 2017, which allows the company to repurchase $100,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to buy up to 13.3% of its shares through open market purchases. Shares repurchase plans are often a sign that the company's leadership believes its stock is undervalued.

Eagle Pharmaceuticals Inc (NASDAQ:EGRX) released its quarterly earnings results on Tuesday, August, 7th. The specialty pharmaceutical company reported $0.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.80 by $0.15. The specialty pharmaceutical company earned $59.30 million during the quarter, compared to the consensus estimate of $51.78 million. Eagle Pharmaceuticals had a net margin of 13.92% and a return on equity of 17.62%. View Eagle Pharmaceuticals' Earnings History.

Eagle Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, February 25th 2019. View Earnings Estimates for Eagle Pharmaceuticals.

4 analysts have issued twelve-month target prices for Eagle Pharmaceuticals' stock. Their forecasts range from $52.00 to $80.00. On average, they expect Eagle Pharmaceuticals' share price to reach $62.50 in the next twelve months. This suggests a possible upside of 49.2% from the stock's current price. View Analyst Price Targets for Eagle Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Eagle Pharmaceuticals.

Media headlines about EGRX stock have been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Eagle Pharmaceuticals earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned media stories about the specialty pharmaceutical company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future.

Some companies that are related to Eagle Pharmaceuticals include Akcea Therapeutics (AKCA), Endo International (ENDP), Ironwood Pharmaceuticals (IRWD), Amicus Therapeutics (FOLD), Insmed (INSM), Portola Pharmaceuticals (PTLA), Heron Therapeutics (HRTX), Supernus Pharmaceuticals (SUPN), Xencor (XNCR), Enanta Pharmaceuticals (ENTA), Zogenix (ZGNX), Endocyte (ECYT), AnaptysBio (ANAB), Mallinckrodt (MNK) and Madrigal Pharmaceuticals (MDGL).

Eagle Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.61%), Park West Asset Management LLC (7.04%), JW Asset Management LLC (2.85%), D. E. Shaw & Co. Inc. (1.91%), Millennium Management LLC (1.91%) and WINTON GROUP Ltd (1.59%). Company insiders that own Eagle Pharmaceuticals stock include David Pernock, Douglas L Braunstein, Pete A Meyers, Proquest Investments Iv, LP, Richard A Edlin, Sander A Flaum, Scott Tarriff and Steven L Krill. View Institutional Ownership Trends for Eagle Pharmaceuticals.

EGRX stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Rothschild & Co. Asset Management US Inc., New York State Common Retirement Fund, JW Asset Management LLC, Bank of New York Mellon Corp, Northern Trust Corp, Canada Pension Plan Investment Board and Amundi Pioneer Asset Management Inc.. Company insiders that have sold Eagle Pharmaceuticals company stock in the last year include Sander A Flaum and Scott Tarriff. View Insider Buying and Selling for Eagle Pharmaceuticals.

EGRX stock was bought by a variety of institutional investors in the last quarter, including Park West Asset Management LLC, Millennium Management LLC, WINTON GROUP Ltd, D. E. Shaw & Co. Inc., Two Sigma Investments LP, Citigroup Inc., Chartwell Investment Partners LLC and Dimensional Fund Advisors LP. Company insiders that have bought Eagle Pharmaceuticals stock in the last two years include David Pernock, Douglas L Braunstein, Pete A Meyers and Richard A Edlin. View Insider Buying and Selling for Eagle Pharmaceuticals.

Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of EGRX stock can currently be purchased for approximately $41.90.

Eagle Pharmaceuticals has a market capitalization of $624.85 million and generates $236.71 million in revenue each year. The specialty pharmaceutical company earns $51.94 million in net income (profit) each year or $3.37 on an earnings per share basis. Eagle Pharmaceuticals employs 108 workers across the globe.

The official website for Eagle Pharmaceuticals is http://www.eagleus.com.

Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at 201-326-5300 or via email at [email protected]